Unresectable Hepatocellular Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Unresectable HCC was defined as a liver tumor that was not amenable to resection therapy given the severity of the disease, including patients who were too ill for surgery because the tumor(s) were located in the liver, patients who were older than 75, or patients who refused surgical treatments. In 2018, there were 841,080 new cases of liver cancer, making it the sixth most common cancer globally and the fourth leading cause of cancer-related mortality. East Asia and Africa continue to have the highest rates of HCC, despite the fact that incidence and mortality are rising in some parts of Europe and the USA. It is best to treat hepatocellular carcinoma (HCC) in a multidisciplinary environment. Tumor size and liver function are the main indicators of resectability prognosis.

Description

Unresectable HCC was defined as a liver tumor that was not amenable to resection therapy given the severity of the disease, including patients who were too sick for surgery because the tumor(s) was/were in the liver, patients who were older than 75, or patients who refused surgical treatments. Depending on the characteristics of the tumor and the state of the liver's functionality, patients with unresectable HCC received locoregional treatment such as percutaneous ethanol injection, transarterial chemoembolization, or the best supportive care. On a small number of people, percutaneous ethanol injection was administered. Such patients are frequently considered candidates for transarterial chemoembolization and the best supportive care.

Unresectable Hepatocellular Cancer (Epidemiology)

In 2018, there were 841,080 new cases of liver cancer, making it the sixth most common cancer globally and the fourth leading cause of cancer-related mortality. East Asia and Africa continue to have the highest rates of HCC, despite the fact that incidence and mortality are rising in a number of regions of Europe and the USA. Since the early 2000s, HCC has been the leading cause of cancer-related death in the USA, according to Surveillance Epidemiology End Results (SEER). By 2030, HCC will be the third leading cause of cancer-related death if current trends continue.

Unresectable Hepatocellular Cancer -Current Market Size & Forecast Trends

The market for unresectable hepatocellular carcinoma (uHCC) is expected to experience significant growth. As of 2023, the market was valued at approximately USD 1.68 billion and is projected to reach about USD 1.90 billion in 2024, with an impressive compound annual growth rate (CAGR) of 13.38%, potentially reaching USD 4.05 billion by 2030. This growth is primarily driven by the increasing incidence of liver cancer, advancements in treatment options such as targeted therapies and immunotherapies, and improved diagnostic techniques. The rising prevalence of risk factors like chronic hepatitis infections and non-alcoholic fatty liver disease further contributes to market expansion. North America is expected to dominate the market due to its advanced healthcare infrastructure, while emerging economies may also see rapid growth as healthcare access improves. Overall, the uHCC market is well-positioned for substantial growth through 2035 as new treatment options continue to develop.

A multidisciplinary approach is best for treating hepatocellular carcinoma (HCC). Tumor size and liver function are the main indicators of resectability prognosis. Only about 5% of people with hepatocellular carcinoma are transplant candidates, but those who may have 5-year survival rates of more than 75% and tumor recurrence rates as low as 15%. Resection, radiofrequency ablation (RFA), and, possibly, systemic therapy with sorafenib (or, if sorafenib fails, with regorafenib, nivolumab, lenvatinib, pembrolizumab, cabozantinib, or ramucirumab) should all be used as a bridge to transplantation or to delay recurrence if possible. Aggressive surgical intervention appears to be associated with the best outcome in patients who experience a recurrence after resection or transplantation. Having a high mortality rate is hepatocellular carcinoma (HCC). Over the past five years, systemic therapy has become a much more viable option. The first multikinase inhibitor for the treatment of HCC was sorafenib, which was made available in 2007. For more than ten years, it was the only systemic therapy that worked. Numerous advancements in the creation of systemic strategies were not made until 2017. After sorafenib, another multikinase inhibitor, lenvatinib, distinguished itself with success and has been used in first-line clinical trials. As second-line treatments, several additional multikinase inhibitors, including regorafenib, ramucirumab, and cabozantinib, were swiftly approved. Immune checkpoint inhibitors (ICIs), which include HCC, have concurrently easily established themselves as treatments for many solid tumors. The ICIs that have received the most attention to date target the proteins CTLA-4, PD-L1, and programmed cell death-1 (PD-1) respectively. These ICIs have proven effective in treating advanced HCC. More recently, the gold-standard first-line therapy was approved using a combination of bevacizumab and atezolizumab (ICI targeting PD-L1). In the second-line setting for patients who did not respond to sorafenib, the combination of ICIs with nivolumab and ipilimumab was also approved. Numerous advanced HCC clinical trials are currently in progress, which will result in ongoing management changes and improve patient survival.

Report Highlights

Unresectable Hepatocellular Cancer - Current Market Trends

Unresectable Hepatocellular Cancer - Current & Forecasted Cases across the G8 Countries

Unresectable Hepatocellular Cancer - Market Opportunities and Sales Potential for Agents

Unresectable Hepatocellular Cancer - Patient-based Market Forecast to 2035

Unresectable Hepatocellular Cancer - Untapped Business Opportunities

Unresectable Hepatocellular Cancer - Product Positioning Vis-a-vis Competitors' Products

Unresectable Hepatocellular Cancer - KOLs Insight